Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease

Ma, Hong; Cui, Fan; Dong, Jingjing; You, Guo-Ping; Yang, Xiao; Lu, Hua-Dong; Huang, Yanling

doi:10.3748/wjg.v20.i40.14950

Cited by 16 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Direct pharmacological administration of adiponectin has been shown to reduce glucose, lipid, and insulin concentrations and increase insulin receptor expression in obese diabetic mice on high fat diet [ 105 ]. A study by Kase et al (2007) reported that treatment with globular adiponectin stimulated NF- κ B of activated B cells and increased the expression of cohesive molecules and MCP-1 in endothelial cells by stimulation of the sphingosine kinase signaling pathway [ 106 ].…”

Section: Adipokines As Therapeutic Targets For Vascular Dysfunctiomentioning

confidence: 99%

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity

husseny

Mamdouh

Shaban

et al. 2017

Journal of Diabetes Research

View full text Add to dashboard Cite

Adipokines are bioactive molecules that regulate several physiological functions such as energy balance, insulin sensitization, appetite regulation, inflammatory response, and vascular homeostasis. They include proinflammatory cytokines such as adipocyte fatty acid binding protein (A-FABP) and anti-inflammatory cytokines such as adiponectin, as well as vasodilator and vasoconstrictor molecules. In obesity and type II diabetes mellitus (DM), insulin resistance causes impairment of the endocrine function of the perivascular adipose tissue, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and an increased production of reactive oxygen species. Recent studies have shown that targeting plasma levels of adipokines or the expression of their receptors can increase insulin sensitivity, improve vascular function, and reduce the risk of cardiovascular morbidity and mortality. Several reviews have discussed the potential of adipokines as therapeutic targets for type II DM and obesity; however, this review is the first to focus on their therapeutic potential for vascular dysfunction in type II DM and obesity.

show abstract

Section: Adipokines As Therapeutic Targets For Vascular Dysfunctiomentioning

confidence: 99%

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity

husseny

Mamdouh

Shaban

et al. 2017

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…Moreover, the overexpression of adiponectin in mice is sufficient to improve insulin sensitivity in high fat diet-induced obesity mice models [ 60 , 61 ]. Recombinant adiponectin administration is sufficient to improve glucose, lipid, and insulin plasma levels as well as insulin receptor expression and liver steatosis in high fat diet-induced obesity mice treated with streptozotocin [ 62 ]. This indicates that adiponectin may ameliorate type 1 diabetes and other obesity-related diseases.…”

Section: Adiponectinmentioning

confidence: 99%

Adipokines as Drug Targets in Diabetes and Underlying Disturbances

Andrade-Oliveira

Câmara

Moraes‐Vieira

2015

Journal of Diabetes Research

139

100

View full text Add to dashboard Cite

Diabetes and obesity are worldwide health problems. White fat dynamically participates in hormonal and inflammatory regulation. White adipose tissue is recognized as a multifactorial organ that secretes several adipose-derived factors that have been collectively termed “adipokines.” Adipokines are pleiotropic molecules that gather factors such as leptin, adiponectin, visfatin, apelin, vaspin, hepcidin, RBP4, and inflammatory cytokines, including TNF and IL-1β, among others. Multiple roles in metabolic and inflammatory responses have been assigned to these molecules. Several adipokines contribute to the self-styled “low-grade inflammatory state” of obese and insulin-resistant subjects, inducing the accumulation of metabolic anomalies within these individuals, including autoimmune and inflammatory diseases. Thus, adipokines are an interesting drug target to treat autoimmune diseases, obesity, insulin resistance, and adipose tissue inflammation. The aim of this review is to present an overview of the roles of adipokines in different immune and nonimmune cells, which will contribute to diabetes as well as to adipose tissue inflammation and insulin resistance development. We describe how adipokines regulate inflammation in these diseases and their therapeutic implications. We also survey current attempts to exploit adipokines for clinical applications, which hold potential as novel approaches to drug development in several immune-mediated diseases.

show abstract

“…Rao et al showed that adiponectin can increase insulin secretion in MIN6 cells [ 32 ]. Moreover, globular adiponectin supplementation increased insulin secretion and decreased glucose levels in rats with Type 2 diabetes and NAFLD [ 33 ]. Several medicinal-herb extracts showed hypoglycemic effects that promoted insulin secretion, in accordance with our results [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Agrimonia pilosa Ledeb. Ameliorates Hyperglycemia and Hepatic Steatosis in Ovariectomized Rats Fed a High-Fat Diet

et al. 2020

View full text Add to dashboard Cite

Estrogen deficiency is associated with obesity, dyslipidemia, and increased insulin resistance in postmenopausal women. An efficient therapeutic agent prevents or improves postmenopausal conditions induced by estrogen deficiency. Here, we investigated the effects of aqueous Agrimonia pilosa Ledeb. extract on glucose and lipid metabolism in ovariectomized rats fed a high-fat diet (HFD). Female Sprague-Dawley rats were sham-operated or ovariectomized, and 3 weeks later were assigned to the following groups: sham-operated + HFD (S); ovariectomized + HFD (OVX); and ovariectomized + HFD with 0.5% A. pilosa aqueous extract (OVX + 0.5A) groups. Ovariectomy significantly increased body weight and dietary intake relative to the S group. However, A. pilosa treatment did not significantly affect weight gain or dietary intake. Blood triacylglycerol, total cholesterol, and low-density lipoprotein cholesterol levels tended to decrease in the A. pilosa-supplemented group. Blood glucose levels were significantly lower in the OVX + 0.5A group than those in the OVX group. Blood adiponectin and insulin concentrations increased significantly after A. pilosa treatment in the ovariectomized group. A. pilosa supplementation tended to decrease liver weights and prevented lipid accumulation. These effects correlated with reduced hepatic expression of lipogenesis-related genes (fatty acid synthase, acetyl-coenzyme A carboxylase alpha, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase). Therefore, A. pilosa may improve metabolic disorders in ovariectomized rats.

show abstract

Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease

Cited by 16 publications

References 22 publications

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity

Adipokines as Drug Targets in Diabetes and Underlying Disturbances

Agrimonia pilosa Ledeb. Ameliorates Hyperglycemia and Hepatic Steatosis in Ovariectomized Rats Fed a High-Fat Diet

Contact Info

Product

Resources

About